Abstract:Background: The infiltration and activation of immune cells in the tumor microenvironment (TIME) affect the prognosis of patients with cancer. Tertiary lymphoid structure (TLS) formation favors tumour- infiltrating-lymphocyte (TIL) recruitment and is regarded as an important indicator of good prognosis associated with immunotherapy in patients with tumors. Chemotherapy is currently one of the most commonly used clinical treatment methods. However, there have been no clear report to explore the effects of different types of chemotherapy on TLS formation in the TIME. This study examined the effects of immunogenic cell death (ICD)-inducing chemotherapeutics on immune cells, high-endothelial venules (HEV), and TLSs in mouse melanomas. Methods: Doxorubicin (an ICD inducer), gemcitabine (non-ICD inducer), and a combination of the two drugs was delivered intra-peritoneally to B16F1-loaded C57BL/6 mice. The infiltration of immune cells into tumor tissues was evaluated using flow cytometry. HEV and TLS formation was assessed using immunohistochemistry and multiple fluorescent immunohistochemical staining. Results: Doxorubicin alone, gemcitabine alone, and the two-drug combination all slowed tumor growth, with the combined treatment demonstrating a more pronounced effect. Compared with the control group, the doxorubicin group showed a higher infiltration of CD8 + T cells and tissue-resident memory T cells (T RM ) and an increase in the secretion of interferon-γ, granzyme B, and perforin in CD8 + T subsets and activation of B cells and dendritic cells. Doxorubicin alone and in combination with gemcitabine decreased regulatory T cells in the TIME. Moreover, doxorubicin treatment promoted the formation of HEV and TLS. Doxorubicin treatment also upregulated the expression of programmed cell death protein (PD)-1 in CD8 + T cells and programmed cell death protein ligand (PD-L)1 in tumor cells. Conclusions: These results indicate that doxorubicin with an ICD reaction promotes TLS formation and increases PD-1/PD-L1 expression in tumor tissues. The results demonstrate the development of a therapeutic avenue using combined immune checkpoint therapy.

Antitumor Effects of Integrin Inhibitor HM-3 and Cyclophosphamide in Mouse Melanoma

Antitumor effects of peptide HM-3 against non-small cell lung cancer xenografts in nude mice

[Corrigendum] in Vitro and in Vivo Activities of an Antitumor Peptide HM-3: A Special Dose-Efficacy Relationship on an HCT‑116 Xenograft Model in Nude Mice.

Effect of honey bee venom on proliferation of K1735M2 mouse melanoma cells in-vitro and growth of murine B16 melanomas in-vivo.

Antitumor Effect of FP3 in Combination with Cetuximab on Patient-Derived Tumor Tissue Xenograft Models of Primary Colon Carcinoma and Related Lymphatic and Hepatic Metastases

Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma

Antitumor Effects of Peptide HM-3 and Gemcitabine against Experimental Lewis Lung Cancer

HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma

Antitumor Activity of Integrin Αvβ3 Antibody Conjugated-Cationic Microbubbles in Liver Cancer.

Cilengitide, an Αvβ3-Integrin Inhibitor, Enhances the Efficacy of Anti-Programmed Cell Death-1 Therapy in a Murine Melanoma Model

Inhibitory effect of harmine derivative B-9-3 combined with five traditional anti-tumor drugs on cancer cells in vitro

Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma

Effect of melatonin on the pancreatic cancer in mice subcutaneous xenograft

An Integrin Αvβ3 Antagonistic Modified Peptide Inhibits Tumor Growth Through Inhibition of the ERK and AKT Signaling Pathways.

Establishment of Three Melanoma Animal Models

Effectiveness of HM-3-HSA on Inhibiting Cancer Cell Migration and Metastasis.

Nimotuzumab increased chemosensitivity of human lung adenocarcinoma docetaxel-resistant cell line

Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma

Antitumor Effect of IL-2 and CIK Cells on Malignant Melanoma in Mice

Therapeutic Effects of Anti-CD90 Monoclonal Antibody in Melanoma

Molecular Mechanisms of Paclitaxel and Nm-3 on Human Gastric Cancer in A Severe Combined Immune Deficiency Mice Orthotopic Implantation Model